Lilly’s ImClone Buy Adds Oncology Candidates And Pipeline Pressures
Executive Summary
Eli Lilly announced Oct. 6 that it is acquiring ImClone for $6.5 billion, confirming rumors that had been circulating since the middle of the previous week. The central question now is whether Lilly can turn the buyout into a win for shareholders
You may also be interested in...
Ramucirumab Becomes First Lilly ImClone Compound To Enjoy Phase III Success
The VEGF2-inhibitor demonstrated an overall survival benefit and prolonged progression-free survival in second-line gastric cancer, Lilly said. The big pharma acquired ramucirumab through its $6.5 billion purchase of ImClone Systems in 2008.
Icahn Is Forest’s Latest Wolf At The Door
Specialty pharma Forest Pharmaceuticals Inc. has already spent months fending off doubts about the future of its pipeline as well as a potential federal ban prohibiting its long-time CEO from negotiating federal contracts. Now, the company has a new wolf at the door: dissident investor Carl Icahn.
Icahn Is Forest’s Latest Wolf At The Door
Specialty pharma Forest Pharmaceuticals Inc. has already spent months fending off doubts about the future of its pipeline as well as a potential federal ban prohibiting its long-time CEO from negotiating federal contracts. Now, the company has a new wolf at the door: dissident investor Carl Icahn.